コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 comes after a second IVIg course in GBS with poor prognosis.
2 that, unlike acute postinfectious GN, has a poor prognosis.
3 ncer aggressiveness, therapy resistance, and poor prognosis.
4 reatment, and the phenotypes associated with poor prognosis.
5 ers), are common and often associated with a poor prognosis.
6 orrelated with known mesenchymal markers and poor prognosis.
7 t failure or arrhythmia is associated with a poor prognosis.
8 al lung with limited therapeutic options and poor prognosis.
9 , characterized by its aggressive course and poor prognosis.
10 smus GBS Outcome Score at week 1 predicted a poor prognosis.
11 me may contribute to disease progression and poor prognosis.
12 the invasive phenotype are associated with a poor prognosis.
13 is a brain tumour with high invasiveness and poor prognosis.
14 tive breast cancer, which is associated with poor prognosis.
15 ted with heightened metastatic potential and poor prognosis.
16 sed in many cancers and this correlates with poor prognosis.
17 ession signature, which were associated with poor prognosis.
18 MLR and NLR were found to be associated with poor prognosis.
19 t a distinct molecular cohort with uniformly poor prognosis.
20 es distant metastases and is correlated with poor prognosis.
21 gnancies, T-cell lymphomas have an extremely poor prognosis.
22 n the link between high collagen density and poor prognosis.
23 High GBP2 expression is associated with poor prognosis.
24 PH) after PEA remains a major determinant of poor prognosis.
25 route itself did not demarcate patients with poor prognosis.
26 growth pattern, it is associated with a very poor prognosis.
27 treatment of ER+ patients (n = 68) predicted poor prognosis.
28 has historically been associated with a very poor prognosis.
29 tures result in its universal recurrence and poor prognosis.
30 te myeloid leukemia (AML) is associated with poor prognosis.
31 ely 3% of gastrointestinal malignancies with poor prognosis.
32 ll carcinomas (RCCs) and carries a decidedly poor prognosis.
33 confers PARPi resistance and correlates with poor prognosis.
34 Primary effusion lymphoma (PEL) has a very poor prognosis.
35 rosine kinase (BTK) inhibitor therapy have a poor prognosis.
36 targeted by hormonal therapies, resulting in poor prognosis.
37 or gene correlate with high-risk disease and poor prognosis.
38 ently detected in recurrent BC patients with poor prognosis.
39 SCC) and lung (LUSC), and is associated with poor prognosis.
40 /STING in human dMMR cancers correlates with poor prognosis.
41 ase-2019 (COVID-19) and is associated with a poor prognosis.
42 ns showed non-significant tendencies towards poor prognosis.
43 nt epithelial tumor of the biliary tree with poor prognosis.
44 is the most frequent primary bone tumor with poor prognosis.
45 2 level and is significantly associated with poor prognosis.
46 as peritoneal carcinomatosis and has a very poor prognosis.
47 ARMS) is an aggressive pediatric cancer with poor prognosis.
48 dvanced colorectal cancer (CRC) have still a poor prognosis.
49 DNMT1, and UHRF1 in HCCs in association with poor prognosis.
50 relatively common cutaneous neoplasm with a poor prognosis.
51 ated signaling was linked to CMS4 tumors and poor prognosis.
52 s (IPF) is a progressive lung disease with a poor prognosis.
53 central nervous system malignancy and has a poor prognosis.
54 n sub-Saharan Africa, KS continues to have a poor prognosis.
55 bone, resulting in pathologic fractures and poor prognosis.
56 ts a new therapeutic option in patients with poor prognosis.
57 resent in 10% of patients, and indicative of poor prognosis.
58 the MYCN oncogene is closely associated with poor prognosis.
59 ared helpful to identify the patients with a poor prognosis.
60 ute myocardial infarction is associated with poor prognosis.
61 Neuroblastoma is a paediatric cancer with a poor prognosis.
62 ss epithelial cancers and is associated with poor prognosis.
63 gressive central nervous system tumor with a poor prognosis.
64 tients, and this increase is associated with poor prognosis.
65 cally aggressive malignancy with a uniformly poor prognosis.
66 reased alpha-fetoprotein concentrations have poor prognosis.
67 species (ROS), downregulated mitophagy, and poor prognosis.
68 ion of MSL3, ZNF691 and VPS45 was related to poor prognosis.
69 ed by cholangiocytic differentiation and has poor prognosis.
70 cytes from melanoma patients correlated with poor prognosis.
71 is a biomarker for pancreatic cancer with a poor prognosis.
72 identify del17p-carrying NDMM patients with poor prognosis.
73 disease with limited therapeutic options and poor prognosis.
74 SaO was not an independent predictor of poor prognosis.
75 with tumorigenesis, tumor size and predicts poor prognosis.
76 associated with high infiltration leading to poor prognosis.
77 faster progression to metastatic disease and poor prognosis.
78 orrelates with refractoriness to therapy and poor prognosis.
79 and correlate with tumor aggressiveness and poor prognosis.
80 leading to elevated PCa cancer stemness and poor prognosis.
81 in the disease process and has an extremely poor prognosis.
82 hly associated with advanced tumor grade and poor prognosis.
83 apsed after stem-cell transplantation have a poor prognosis.
84 tween elevated MDA-9 and bone metastasis and poor prognosis.
85 eased cancer cell migration, metastasis, and poor prognosis.
86 h intratumoral CD8+ T cell infiltration, but poor prognosis.
87 of protein expression, were associated with poor prognosis.
88 rapy, and long-term complications leading to poor prognosis.
89 ression of RAC1 and RAC2 was associated with poor prognosis.
90 ar carcinomas characterized by comparatively poor prognosis.
91 f a subset of HCC patients with a relatively poor prognosis.
92 portopulmonary hypertension (PoPH) carries a poor prognosis.
93 LC, and their lower level is associated with poor prognosis.
94 D in the kidney allograft is associated with poor prognosis.
95 clinical challenge that generally portends a poor prognosis.
96 embrane oxygenation has been associated with poor prognosis.
97 , TNBC is challenging to treat and carries a poor prognosis.
98 IV who have haematological malignancies with poor prognosis.
99 state cancer progression and correlates with poor prognosis.
100 tes strongly with elevated CD73 activity and poor prognosis.
101 roups associated with DNA repair defects and poor prognosis.
102 scale [mRS]), and phenotypes associated with poor prognosis.
103 nce of 3%-7% progressing to ARF, a marker of poor prognosis.
104 rexpressed in human OS and correlates with a poor prognosis.
105 errations show significant associations with poor prognosis.
106 tion of Ezh2, similar to ACC patients with a poor prognosis.
107 f leptomeningeal metastases is indicative of poor prognosis.
108 ntially expressed genes that correlated with poor prognosis.
109 ancer with steadily increasing incidence and poor prognosis.
110 odialysis (ESRD-HD) and aortic stenosis have poor prognosis.
111 eloid leukemia (AML) and are associated with poor prognosis.
112 ogression, which is significantly related to poor prognosis.
113 ssociated with a high rate of recurrence and poor prognosis.
114 (LUSC) is a highly metastatic disease with a poor prognosis.
115 in the majority of cancers, often conferring poor prognosis.
116 er aneuploidy are frequently associated with poor prognosis.
117 sm, invasive and metastatic progression, and poor prognosis.
118 cluster, NOTCH1 mutation was associated with poor prognosis.
121 though advanced bladder cancer overall has a poor prognosis, a subset of patients demonstrate durable
125 eading cause of cancer death worldwide, with poor prognosis and a high rate of recurrence despite ear
127 creased tolerance to antineoplastic therapy, poor prognosis and accelerated death, with no approved t
129 ias and T-cell lymphomas (TCLs) still have a poor prognosis and an inadequate response to current the
132 s constitutes a novel targeted therapy for a poor prognosis and frequently chemoresistant group of pa
134 h intratumoral nerve density correlates with poor prognosis and high recurrence across multiple solid
135 ymphocytic leukemia, this is associated with poor prognosis and increased chemotaxis; in B-cell acute
141 mary pediatric malignancy of the bone having poor prognosis and long-term survival rates of less than
142 DLBCL), and the existence of a subgroup with poor prognosis and phenotypic proximity to Burkitt lymph
143 p53- and PTEN-deficiency is associated with poor prognosis and poor response to anticancer therapies
144 P4K3 in human lung cancer is associated with poor prognosis and recurrence, however, the role of GLK
146 nes, which have been shown to correlate with poor prognosis and the development of sepsis-related seq
147 nt pleural mesothelioma (MPM) has an overall poor prognosis and unsatisfactory treatment options.
148 RNF4 protein and mRNA levels correlate with poor prognosis and with resistance to MAPK inhibitors.
149 decreased in breast cancer, correlates with poor prognosis, and appears to be driven by adenosine th
150 es has been associated with drug resistance, poor prognosis, and disease relapse in many tumor types.
151 eased metastatic potential and cell seeding, poor prognosis, and enhanced recruitment of tumor-associ
152 noma (HCC) is difficult to detect, carries a poor prognosis, and is one of few cancers with an increa
154 ine carcinomas (ANECs) are rare lesions with poor prognosis, and the molecular etiology is only parti
155 tinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent
156 ated macrophages (TAMs) were associated with poor prognosis, and we established the inflammatory role
157 to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness-implementati
160 tivity and tamoxifen agonism, explaining the poor prognosis associated with neurofibromin loss in end
164 3, Axl, and Mertk) are often correlated with poor prognosis because of their capacities to sustain an
166 it had significant positive correlation with poor prognosis beyond five years in both postmenopausal
167 -cell lymphoma, angiogenesis correlates with poor prognosis, but attempts to target established proan
168 cardial infarction (AMI) have an exceedingly poor prognosis, but it is unknown to what extent guideli
169 en associated with cancer aggressiveness and poor prognosis by triggering proangiogenic and antiapopt
170 ith minimisation factors of surgical centre, poor prognosis cancer, and previous adjuvant treatment w
172 ted with detection of a higher proportion of poor-prognosis cancers than was digital mammography.
173 orithm separates patients into favorable and poor prognosis cohorts, where higher TILs scores were as
175 ndings illustrate that CRC patients may have poor prognosis despite high CD8+ T cell infiltration and
176 diagnosed with advanced HIV infection have a poor prognosis despite initiation of combined antiretrov
178 (30%) underwent vitrectomy, and 5 (50%) with poor prognosis did not undergo vitreoretinal surgery.
181 women diagnosed with breast cancer (BC) have poor prognosis due to increased rates of metastasis.
182 However, patients with KIRC usually have poor prognosis due to limited biomarkers for early detec
186 hibits a triple-negative phenotype and has a poor prognosis, even with traditional chemical and anti-
188 ermore, a high expression of SFRP1 predicted poor prognosis for ampullary adenocarcinoma patients.
194 ike tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently relapse, and die as a result
195 neic hematopoietic cell transplantation have poor prognosis, highlighting an unmet therapeutic need.
196 patients with cancer and are associated with poor prognosis; however, their role in transplantation i
198 rs and older, and notably for cancers with a poor prognosis (ie, oesophagus, stomach, pancreas, and l
212 ased HSATII copy number is associated with a poor prognosis in colon cancer, and in human cytomegalov
216 d protein levels of ERalpha, associates with poor prognosis in ER-positive breast cancer patients.
218 p120ctn) and EGFR, two genes associated with poor prognosis in ESCC, work together to cause invasion.
219 iable analysis, miR-4516 was correlated with poor prognosis in GBM patients (HR = 1.49, 95%CI: 1.12-1
222 -associated recurrence is the major cause of poor prognosis in hepatocellular carcinoma (HCC), howeve
231 elements, leading to TERT overexpression and poor prognosis in neuroblastoma, but TERT-associated onc
236 expression was an independent predictor for poor prognosis in patients with lung cancer.Conclusions:
237 the abundance of IRF4+ Tregs correlated with poor prognosis in patients with multiple human cancers.
238 with cancer-free tissues and correlated with poor prognosis in patients with NSCLC harboring mutant E
240 rdiomyopathy and is the major contributor to poor prognosis in patients with systemic amyloidosis.
241 em/progenitor marker NES was associated with poor prognosis in PN GBM patients, indicating a unique r
242 of INCENP were significantly associated with poor prognosis in primary tumors of neuroblastoma patien
245 ve HIV-associated lymphoma with a relatively poor prognosis in the era of effective HIV therapy.
249 tastasis formation, which is associated with poor prognosis in triple-negative breast cancer (TNBC).
254 se overexpressed in human OC associated with poor prognosis, is essential for OC progression principa
255 er kidney transplant that is associated with poor prognosis, is not a specific entity but rather the
256 associating with therapeutic resistance and poor prognosis, its global or lung epithelial-specific d
257 s a recalcitrant cancer, i.e., a cancer with poor prognosis, lacking progress in diagnosis and treatm
260 ory subtype of renal cancer characterized by poor prognosis, markers of T cell dysfunction, and alter
269 cement pathways have been altered due to the poor prognosis of intubated patients and the risk of tra
270 that higher levels of ZNF281 correlate with poor prognosis of patients treated with DNA-damaging the
271 ased incidence of cardiovascular disease and poor prognosis of patients with chronic heart failure (H
275 ic thyroid cancer (ATC) is aggressive with a poor prognosis, partly because of the immunosuppressive
277 orme (GBM) is a malignant brain tumor with a poor prognosis resulting from tumor resistance to antica
280 ta-catenin-independent function of BCL9 in a poor-prognosis subtype of CRC tumors characterized by ex
281 tly associated with higher tumor burden, and poor prognosis, suggesting their relevance in hepatocarc
282 ntact, with VSVZ + GBM patients displaying a poor prognosis, the VSVZ + GBMs do not possess a distinc
283 and lethal human malignancies with extremely poor prognosis, there is an urgent demand of more effect
284 tronic health record and is used to indicate poor prognosis, to describe conflict with families, and
286 and immune response that are associated with poor prognosis were discovered including HMGCS2, GPX2 an
287 PEL is an aggressive disease with extremely poor prognosis when treated with conventional chemothera
288 egulated immunoregulation is associated with poor prognosis, whereas early innate signaling and Th1-s
289 involvement was common and associated with a poor prognosis, whereas opsoclonus, female sex, and youn
290 a implicate IgL translocation as a driver of poor prognosis which may be due to IMiD resistance.
291 Finally high MYO18B expression reflects poor prognosis while high MYL5 or MYO1B expression refle
292 metastatic uveal melanoma, which has a very poor prognosis with a median survival of less than 1 y.
293 ted recurrent thyroid carcinomas have a very poor prognosis with a median survival of less than a yea
296 ry access issues) and were associated with a poor prognosis, with a very high in-hospital and late de
298 id tumor, where MYCN amplification heralds a poor prognosis, with only 11% of high-risk patients surv
299 ression of Keratin 14, a known biomarker for poor prognosis, with p = 2 x 10-45 for within-tumor test
300 cancers and its expression is predictive of poor prognosis within this aggressive breast cancer subt